Pharma — August 2023
-
Kilde: Nordnet
-
Amerikanske Merck opjusterer efter stærkt kvartal
https://www.proinvestor.com/investornyt/1025072/amerikanske-merck-opjusterer-efter-staerkt-kvartal -
8.8.2023 07.29 • MarketWire •
Kursmålet for Lundbeck hæves til 46 kr. fra 44 kr. af Nordea, der fastholder anbefalingen "køb".Det viser data fra Bloomberg.
Lundbeck-aktien sluttede mandag i 35 kr. efter en stigning på 0,8 pct. Aktien er siden nytår steget godt 34 pct.
.\˙ MarketWire
-
Is AbbVie Still a Good Dividend Stock to Buy? https://www.proinvestor.com/investornyt/1030213/is-abbvie-still-a-good-dividend-stock-to-buy
-
Gilead Sciences a Top 25 Dividend Giant With 3.75% Yield (GILD) https://www.proinvestor.com/investornyt/1031382/gilead-sciences-a-top-25-dividend-giant-with-375-yield-gild
-
Dagens aktie er Danaher Corporation
Danaher Corporation designer, fremstiller og markedsfører professionelle, medicinske, industrielle og kommercielle produkter og tjenester over hele verden.
Samling af 20 driftsselskaber.
Virksomheden opererer gennem tre segmenter: Life Sciences, Diagnostics og Environmental & Applied Solutions.
https://www.proinvestor.com/boards/114611 -
Up 45% This Year What's Driving The Growth For Eli Lilly Stock? https://www.proinvestor.com/investornyt/1033881/up-45-this-year-whats-driving-the-growth-for-eli-lilly-stock
-
Is Amgen Stock Fully Valued After A 17% Rise In A Month? https://www.proinvestor.com/investornyt/1034482/is-amgen-stock-fully-valued-after-a-17-rise-in-a-month
-
Lundbeck Q2: Slår konsensus over hele linjen https://www.proinvestor.com/boards/114728
-
Fortsat vækst og lave omkostninger sikrer opjustering hos Lundbeck https://www.proinvestor.com/investornyt/1035293/fortsat-vaekst-og-lave-omkostninger-sikrer-opjustering-hos-lundbeck
-
Danske Bank skærer kursmålet for ALK: Bekymringerne over tabletsalget i Europa fortsætter https://www.proinvestor.com/investornyt/1035263/danske-bank-skaerer-kursmalet-for-alk-bekymringerne-over-tabletsalget-i-europa-fortsaetter
-
Lundbeck (+2,7%, 42,50) får efter onsdagens regnskab hævet anbefalingen til "køb" fra "hold" af finanshuset Morningstar.
Det viser data fra Bloomberg News. Kursmålet fastholdes på 42,50 kr. Marketwire -
Novartis planlægger børsnotering af Sandoz i oktober https://www.proinvestor.com/investornyt/1036942/novartis-planlaegger-borsnotering-af-sandoz-i-oktober
-
Lundbeck må tage afsked med direktør for HR- og kommunikation https://www.proinvestor.com/investornyt/1036831/lundbeck-ma-tage-afsked-med-direktor-for-hr-og-kommunikation
-
Børshuse ser fortsat Lundbecks prognose som konservativ trods opjustering https://www.proinvestor.com/investornyt/1038238/borshuse-ser-fortsat-lundbecks-prognose-som-konservativ-trods-opjustering
-
ALK-Abelló - halvårsrapport
https://www.proinvestor.com/boards/114899 -
ALK- et kvartalsregnskaber uden allergiske reaktioner https://www.proinvestor.com/boards/114901
ja dejligt med Teva tog lige toppen af min position 
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind